The Union Ministry of Health and Family Welfare on Wednesday endorsed the recommendation of the Drugs Technical Advisory Board (DTAB) to revoke the ban on pioglitazone — an oral anti-diabetic drug which was banned on June 18. The drug will now be sold with a box warning (that the drug carries a significant risk of serious or even life-threatening adverse effects) and will also carry an inset. Doctors will also be told that pioglitazone should not be prescribed as the first line of treatment.